ALK and neoplasm: Similarly, the phase I/II of alectinib and bevacizumab is recruiting (NCT02521051), and brigatinib and bevacizumab in a treatment-refractory setting (NCT04227028), as ALK is known to be a pro-angiogenic tumor.